Covered recipient · General Payments record
RYAN GENTZLER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2019–2025
$61,784.13
- Reported across 59 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,630.00 | 5 |
| Food and Beverage | $211.29 | 3 |
| Education | $105.00 | 2 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $4,990.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,552.50 | 1 |
| ABBVIE INC. | $1,087.50 | 2 |
| AstraZeneca UK Limited | $134.58 | 1 |
| Daiichi Sankyo Inc. | $105.00 | 2 |
| TAIHO ONCOLOGY, INC. | $42.17 | 1 |
| Merck Sharp & Dohme Corporation | $34.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $725.00 | 06/24/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1201913870 | CMS |
| ABBVIE INC. | $362.50 | 10/09/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1201913872 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,050.00 | 04/02/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1206626626 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,940.00 | 07/01/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1206209440 | CMS |
| AstraZeneca UK Limited | $134.58 | 02/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202955440 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,552.50 | 09/04/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1222800745 | CMS |
| Daiichi Sankyo Inc. | $52.50 | 07/17/2025 | Education | Undisputed | 06/30/2026 | 1197019017 | CMS |
| Daiichi Sankyo Inc. | $52.50 | 07/17/2025 | Education | Undisputed | 06/30/2026 | 1197090131 | CMS |
| Merck Sharp & Dohme LLC | $34.54 | 11/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238004988 | CMS |
| TAIHO ONCOLOGY, INC. | $42.17 | 02/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1211408139 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.